Islay Capital Management’s FibroBiologics FBLG Stock Holding History

Islay Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-169	Closed	-$160	–	223
2026 Q2	$160	Hold	169	–	–	﹤0.01%	221
2026 Q1	$223	Sell	169 -1	-0.6%	-$6	﹤0.01%	197
2025 Q4	$763	Hold	170	–	–	﹤0.01%	201
2025 Q3	$1.85K	Buy	170 +147	+639%	+$1.76K	﹤0.01%	192
2025 Q2	$280	Buy	+23	New	+$415	﹤0.01%	198

Other funds holding FBLG

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Islay Capital Management's FBLG Position: Q3 2026 in Review

Islay Capital Management sold out of FibroBiologics (FBLG) in Q3 2026, closing a stake of 169 shares — an estimated $160 sold.

Islay Capital Management first reported a position in FBLG in Q2 2025 and held it in 5 quarters. The position peaked at $1.85K in Q3 2025. 6 funds tracked by Wall St. Rank hold FBLG as of Q3 2026.

Islay Capital Management reported no remaining FibroBiologics position as of Q3 2026 after selling out during the quarter.
Islay Capital Management sold 169 FibroBiologics shares in Q3 2026, an estimated $160.
Islay Capital Management first reported a position in FibroBiologics in Q2 2025 and held it in 5 quarters.
Islay Capital Management's FibroBiologics position peaked at $1.85K in Q3 2025.
6 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2026.

Based on Islay Capital Management's 13F filing for Q3 2026, filed 20 Oct 2026.